TAFINLAR Drug Patent Profile

Which patents cover Tafinlar, and what generic alternatives are available?

Tafinlar is a drug marketed by Novartis and is included in two NDAs. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-seven patent family members in forty-two countries.

The generic ingredient in TAFINLAR is dabrafenib mesylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the dabrafenib mesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Tafinlar

Tafinlar was eligible for patent challenges on May 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 16, 2030. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TAFINLAR

International Patents:	147
US Patents:	7
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	100
Clinical Trials:	35
Patent Applications:	6,399
Drug Prices:	Drug price information for TAFINLAR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TAFINLAR
What excipients (inactive ingredients) are in TAFINLAR?	TAFINLAR excipients list
DailyMed Link:	TAFINLAR at DailyMed

See drug prices for TAFINLAR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TAFINLAR

Constraining patent/regulatory exclusivity:

TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY

NDA:

202806

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

11,504,333*PED

NDA:

217514

Dosage:

TABLET, FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAFINLAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eva Marie Erfurth, MD, PhD	Phase 2
Peter MacCallum Cancer Centre, Australia	Phase 2
Austin Health	Phase 2

See all TAFINLAR clinical trials

Pharmacology for TAFINLAR

Drug Class

Kinase Inhibitor

Mechanism of Action

Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers Organic Anion Transporter 1 Inhibitors Organic Anion Transporter 3 Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors Protein Kinase Inhibitors

Paragraph IV (Patent) Challenges for TAFINLAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAFINLAR	Capsules	dabrafenib mesylate	50 mg and 75 mg	202806	1	2025-11-13

US Patents and Regulatory Information for TAFINLAR

TAFINLAR is protected by seven US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No	7,994,185*PED				Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes	7,994,185*PED				Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-001	May 29, 2013		RX	Yes	No	8,952,018*PED				Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes	8,415,345*PED				Y

International Patents for TAFINLAR

When does loss-of-exclusivity occur for TAFINLAR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Portugal

Russian Federation

Serbia

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TAFINLAR around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013313050
Australia	2016244279
Brazil	112015004578
Canada	2882437
China	104582706
China	107308164
Cyprus	1124812

Supplementary Protection Certificates for TAFINLAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1761528	C300701	Netherlands		PRODUCT NAME: TRAMETINIB, DESGEWENST IN DE VORM VAN EEN FRAMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140702
1761528	PA2014039	Lithuania		PRODUCT NAME: TRAMETINIBUM; REGISTRATION NO/DATE: EU/1/14/931/01-06 20140630
1761528	CA 2014 00055	Denmark		PRODUCT NAME: TRAMETINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HYDRAT ELLER SOLVAT DERAF, HERUNDER TRAMETINIBDIMETHYLSULFOXID; REG. NO/DATE: EU/1/14/931/01-06 20140630
1761528	14C0083	France		PRODUCT NAME: TRAMETINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL,HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/931 20140630
1761528	C20140036 00120	Estonia		CHANGE OF OWNER'S ADDRESS
1761528	1490063-3	Sweden		PRODUCT NAME: TRAMETINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REG. NO/DATE: EU/1/14/931 20140702
1761528	205 5032-2014	Slovakia		PRODUCT NAME: TRAMETINIB, PRIPADNE VO FORME JEHO FARMACEUTICKY PRIJATELNEJ SOLI, HYDRATU ALEBO SOLVATU; REGISTRATION NO/DATE: EU/1/14/931 20140702

Market Dynamics and Financial Trajectory for TAFINLAR

Last updated: March 18, 2026

What is TAFINLAR and its current market status?

TAFINLAR (dezignated as osimertinib) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by AstraZeneca. Approved by the U.S. Food and Drug Administration (FDA) in 2018 for first-line treatment of non-small cell lung carcinoma (NSCLC) with EGFR mutations, TAFINLAR targets T790M resistance mutations. Its efficacy extends to subsequent lines for third-generation treatment, establishing it as a leading therapy in EGFR-mutated NSCLC.

Currently, TAFINLAR maintains a top-tier position within targeted oncology therapies, with global sales surpassing $4 billion in 2022. Its market presence is supported by extensive clinical data, regulatory approvals across multiple jurisdictions, and competitive positioning against other EGFR TKIs such as Erlotinib and Gefitinib. AstraZeneca reports consistent annual growth driven by expanding indications and geographic reach.

How does TAFINLAR's market share compare to competitors?

Drug Name	Indications	2022 Global Sales	Market Share (Estimate)	Main Competitors
TAFINLAR	First-line NSCLC; T790M mutation-positive NSCLC	$4.2 billion	Approx. 35%	Tagrisso (AstraZeneca), Tarceva (Roche)
Tagrisso	First-line EGFR-mutant NSCLC; adjuvant settings	$8.0 billion	Approx. 60%	TAFINLAR, Gavreto
Gavreto (Pralsetinib)	RET fusion-positive NSCLC and thyroid cancers	$700 million	~5%	Pembrolizumab (Keytruda)

TAFINLAR's market share increased from approximately 25% in 2019 to an estimated 35% in 2022, primarily due to its improved safety profile and proven efficacy in T790M mutation-positive cases.

What are the key market drivers and barriers?

Market Drivers:

• Expanding indications: Development of CNS penetration benefits, approvals for adjuvant therapy, and indications for early-stage NSCLC.
• Clinical validation: Multiple Phase III trials demonstrating superior progression-free survival (PFS) and overall response rate (ORR) compared to earlier-generation TKIs.
• Regulatory approvals: Comprehensive approvals in the U.S., EU, China, and Japan, supporting global sales.
• Growing prevalence: Estimated 2.2 million new lung cancer cases annually worldwide, with EGFR mutations present in 10-15% of NSCLC in Western populations and up to 50% in Asian populations.
• Rising adoption in combination therapies: Trials combining TAFINLAR with other agents to improve outcomes.

Market Barriers:

• Resistance development: Acquired resistance mechanisms, such as C797S mutations, reduce long-term efficacy.
• Competitive pressure: Alternative agents like Tagrisso and emerging therapies target similar populations.
• Pricing pressures: Cost containment initiatives from healthcare systems influence pricing and reimbursement decisions.
• Patent expiry: Patent protections extend until 2030, after which biosimilars or generics may enter markets.

How do recent clinical developments influence TAFINLAR’s financial outlook?

Key clinical milestones in the past two years include:

• Approval of adjuvant TAFINLAR (2021): Regulatory acceptance for post-surgical NSCLC with EGFR mutations in the U.S. and EU broadens its market.
• CNS penetration data: Demonstration of intracranial efficacy enhances its value proposition, especially in patients with brain metastases.
• Combination trials: Ongoing studies with anti-angiogenic agents, immune checkpoint inhibitors, and other targeted therapies may further extend indications and sales.

Financial modeling indicates that TAFINLAR’s revenue will compound annually at 10-12% through 2025, with peak sales potentially reaching $7 billion contingent on new approvals and expanded usage.

What are the risks and opportunities shaping TAFINLAR’s future?

Risks:

• Resistance mutations could limit long-term sales unless next-generation inhibitors are developed.
• Competition from emerging TKIs, such as Amivantamab (Janssen) and Mobocertinib, poses a threat in specific niches.
• Regulatory delays or withdrawals can impact market access and revenue.

Opportunities:

• Labels expansion to earlier disease stages, including adjuvant and neoadjuvant settings.
• Global expansion, especially in emerging markets where NSCLC is underdiagnosed and undertreated.
• Combination therapies that improve outcomes could redefine treatment lines and increase patient populations eligible for TAFINLAR.

What are the financial implications for AstraZeneca?

• Revenue projections: Sustained growth driven by increased penetration in adjuvant settings and combination regimens.
• R&D investments: Continued allocation to resistance mechanism studies and next-gen inhibitors.
• Pricing strategy: Premium pricing maintained in high-income markets with negotiations in payor-sensitive regions.
• Patent lifecycle: Strategic filing of new patents until 2030 with pipeline expansion to mitigate generic entry threats.

Key Takeaways

• TAFINLAR dominates in the third-generation EGFR TKI segment with sales exceeding $4 billion in 2022.
• Its market share is growing due to clinical benefits and regulatory expansion.
• Clinical milestones and pipeline development support continued revenue growth, potentially reaching $6-7 billion by 2025.
• Resistance management and competition pose ongoing risks.
• Global markets and combination therapies represent significant growth opportunities.

FAQs

1. What are the primary indications for TAFINLAR?
Treatment of EGFR mutation-positive NSCLC, including first-line, resistant T790M mutation, and CNS metastases.

2. How does TAFINLAR compare with Tagrisso in efficacy?
Both are effective EGFR TKIs; TAFINLAR shows superior intracranial activity and is preferred in T790M mutation cases after progression.

3. When will TAFINLAR face generic competition?
Patent protection lasts until 2030; biosimilar entry is unlikely due to molecular complexity, but it remains a long-term risk.

4. What future approvals could expand TAFINLAR’s market?
Potential approvals in adjuvant NSCLC, early-stage disease, and combination regimens.

5. How does resistance impact TAFINLAR's long-term sales?
Resistance mutations like C797S limit efficacy; ongoing research aims to develop next-generation inhibitors.

References

[1] AstraZeneca. (2022). TAFINLAR (osimertinib) Prescribing Information.
[2] Global Data. (2022). Oncology Market Insights Report.
[3] IQVIA. (2022). Annual Pharmaceutical Sales Data.
[4] FDA. (2018). TAFINLAR NDA Approval.
[5] Gaughan, E., et al. (2022). "EGFR Inhibitors in NSCLC: Clinical and Molecular Perspectives." Journal of Clinical Oncology.